Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06572735
What this trial is testing

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hospices Civils de Lyon 50
Testing effectiveness (Phase 2)Ended earlyNCT03397394
What this trial is testing

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaMetastatic Urothelial Carcinoma+5 more
pharmaand GmbH 97
Not applicableStudy completedNCT04774627
What this trial is testing

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Who this might be right for
Cancer
University Hospital, Caen 200
Testing effectiveness (Phase 2)Ended earlyNCT02769962
What this trial is testing

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Who this might be right for
Urothelial CarcinomaUrothelial CancerLung Neoplasms+2 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Large-scale testing (Phase 3)Looking for participantsNCT07472140
What this trial is testing

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancersPrimary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre 120
Early research (Phase 1)Study completedNCT04672460
What this trial is testing

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsSolid TumorsOvarian Cancer+5 more
Pfizer 73
Early research (Phase 1)Study completedNCT00678132
What this trial is testing

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Who this might be right for
Neoplasms
National Cancer Institute (NCI) 23
Testing effectiveness (Phase 2)Ended earlyNCT04826198
What this trial is testing

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Who this might be right for
Ovarian Cancer
Gustave Roussy, Cancer Campus, Grand Paris 13
Testing effectiveness (Phase 2)Looking for participantsNCT04681469
What this trial is testing

Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Gruppo Oncologico del Nord-Ovest 49
Testing effectiveness (Phase 2)Study completedNCT03601923
What this trial is testing

Niraparib in Patients With Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Dana-Farber Cancer Institute 32
Early research (Phase 1)Study completedNCT00515866
What this trial is testing

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Who this might be right for
Pancreatic Neoplasms
AstraZeneca 68
Large-scale testing (Phase 3)Study completedNCT02975934
What this trial is testing

Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 405
Testing effectiveness (Phase 2)Study completedNCT04669002
What this trial is testing

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Ellipses Pharma 34
Testing effectiveness (Phase 2)Study completedNCT01074970
What this trial is testing

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Who this might be right for
Breast Cancer
Hoosier Cancer Research Network 135
Testing effectiveness (Phase 2)UnknownNCT04633902
What this trial is testing

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Who this might be right for
Metastatic Melanoma
California Pacific Medical Center Research Institute 41
Early research (Phase 1)Study completedNCT05038839
What this trial is testing

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
M.D. Anderson Cancer Center 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT04194554
What this trial is testing

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 102
Early research (Phase 1)Study completedNCT00633269
What this trial is testing

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Who this might be right for
Neoplasm Metastasis
AstraZeneca 6
Next Page